Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginInterest Coverage RatioInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on SalesTimes Interest Earned

Centessa Pharmaceuticals (CNTA) FCF Margin (2022 - 2025)

Centessa Pharmaceuticals (CNTA) has disclosed FCF Margin for 3 consecutive years, with 381.64% as the latest value for Q1 2025.

  • On a quarterly basis, FCF Margin changed N/A to 381.64% in Q1 2025 year-over-year; TTM through Sep 2025 was 1206.96%, a 627961.0% decrease, with the full-year FY2023 number at 2342.2%, changed N/A from a year prior.
  • FCF Margin was 381.64% for Q1 2025 at Centessa Pharmaceuticals, down from 1209.26% in the prior quarter.
  • In the past five years, FCF Margin ranged from a high of 3636.18% in Q2 2022 to a low of 381.64% in Q1 2025.
  • A 3-year average of 1948.44% and a median of 2034.55% in 2022 define the central range for FCF Margin.
  • Biggest YoY gain for FCF Margin was -56131bps in 2023; the steepest drop was -183732bps in 2023.
  • Centessa Pharmaceuticals' FCF Margin stood at 2371.3% in 2022, then tumbled by -49bps to 1209.26% in 2023, then crashed by -132bps to 381.64% in 2025.
  • Per Business Quant, the three most recent readings for CNTA's FCF Margin are 381.64% (Q1 2025), 1209.26% (Q4 2023), and 1473.24% (Q3 2023).